Coursera (NYSE:COUR) stock is dropping on Tuesday after the company released its earnings report for the first quarter of 2024.
Lackluster guidance in that report is why shares are falling this morning. That includes its revenue guidance of $162 to $166 million for the second quarter of the year. This would miss Wall Street’s estimate of $177.82 million for the quarter.
Coursera’s revenue guidance of $695 to $705 million for the full year of 2024 also leaves much to be desired. It wouldn’t come close to reaching analysts’ 2024 revenue estimate of $736.45 million.
Coursera CEO Jeff Maggioncalda said the following in the earnings report:
“We are in the very early stages of helping our learners, educators, and customers understand how emerging AI technologies will transform the way we teach, learn, and work.”
COUR Stock Hit By Mixed Earnings
Also keeping COUR shares down is the company’s adjusted EPS of 7 cents and revenue of $169.1 million. These are mixed results next to Wall Street’s estimates of 1 cent per share and revenue of $170.4 million.
Even if those results are mixed, it’s worth noting they’re improvements year-over-year. For comparison, the company’s adjusted EPS and revenue for Q1 2023 was -3 cents and $147.6 million.
COUR stock is down 15.5% as of Tuesday morning and was down 38.4% year-to-date when markets closed yesterday.
There are even more stock market stories traders need to know about below!
We have all of the hottest stock market news for Tuesday! That includes everything happening with shares of Medifast (NYSE:MED) stock, Greenwave Technology Solutions (NASDAQ:GWAV) stock and Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock this morning. All of that news is ready to go at the following links!
More Stock Market News for Tuesday
- Why Is Medifast (MED) Stock Down 20% Today?
- Why Is Greenwave Technology Solutions (GWAV) Stock Up 15% Today?
- Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
